

CURRENT REPORT 12/2022

July 8th, 2022

Information on a potential supply of shares in connection with the expiration of the lock-up period for shares under the Stock Grant Program

The Management Board of Ryvu Therapeutics S.A. with its registered office in Krakow ("Company") in connection with the Company's Stock Grant Program for 2021-2024 (the "Incentive Program"), announces that as of July 9, 2022, the lock-up period for a total of 463.743 Company shares, which were granted to a total of 228 employees and associates of the Company under the Incentive Program, will expire.

The Company's Management Board, in order to assess the risk of an oversupply of the Company's shares on the market after the expiration of the first lock-up period, conducted an anonymous survey among the Incentive Program participants regarding potential interest in sale of the Company's shares during the 30-day period falling after the end of the lock-up period. A total of 55,7% of the Incentive Program participants participated in the survey. According to the declarations made in response to the questionnaire, only five participants of the Incentive Program declared their interest in selling a total of 6.291 shares in the Company within 30 days after the expiration of the first lock-up period at a price of PLN 40 or less per share.

The survey conducted was non-binding in nature, the declarations made in response to the survey do not create a binding commitment to sell the Company's shares. The Company's Management Board cannot guarantee that the actual supply of the Company's shares after the end of the first lock-up period will not differ from the declared one.

The Company reported on the Incentive Program in current reports no. 10/2021 dated April 20, 2021 and no. 14/2021 dated May 17, 2021.

Legal basis: Article 17.1 of MAR

Representatives of the Company:

- Paweł Przewięźlikowski – President of the Management Board
- Kamil Sitarz – Vice President of the Management Board